CDSCO Import Licence for Medical Devices in India: MD-14 to MD-15 Process
What Is a CDSCO Import Licence for Medical Devices?
A CDSCO Import Licence is a mandatory statutory authorization issued under Rule 34 of the Medical Devices Rules, 2017. No notified medical device or IVD can clear Indian Customs or be commercially distributed in the Indian market without a valid Form MD-15.
The licensing framework ensures that imported products meet strict Indian standards for safety, quality, performance, and regulatory compliance.
Form MD-14 vs. Form MD-15
Form MD-14: The formal statutory application submitted by the Authorised Indian Agent to the CDSCO asking for permission to import a specific device (or family of devices) manufactured at a specific foreign site.
Form MD-15: The final regulatory certificate issued by the Central Licensing Authority upon successful evaluation of the MD-14 filing. MD-15 serves as the legal import licence presented to Indian Port Health Officers (PHO) and Customs officials.
Who Needs a CDSCO Import Licence?
Under MDR, 2017, all notified medical devices—ranging from low-risk surgical dressings to high-risk active implantable devices and diagnostic reagents—require regulatory approval prior to import into India.
Risk-Based Medical Device Classification
CDSCO categorizes devices into four distinct risk classes under Rule 4 of MDR, 2017. Device classification dictates the technical documentation depth, regulatory fee structures, and audit probability.
Class A (Low Risk): Basic surgical instruments, absorbent cotton, non-invasive supports.
Class B (Low-Moderate Risk): Hypodermic needles, suction pumps, diagnostic X-ray equipment.
Class C (Moderate-High Risk): Hemodialysis machines, lung ventilators, bone fixation plates, complex diagnostic assays.
Class D (High Risk): Drug-eluting cardiac stents, pacemakers, heart valves, IVD assays detecting high-risk pathogens (e.g., HIV, Hepatitis).
Note: Classification should always be verified against official CDSCO classification lists (published and updated periodically on the CDSCO portal) or evaluated using First Schedule parameters of MDR, 2017.
Eligibility & The Authorised Indian Agent (AIA)
A foreign manufacturer cannot apply directly for a CDSCO import licence without an established legal entity in India.
POWER OF ATTORNEY
Foreign Manufacturer - Authorised Indian Agent│
(Overseas Site) - (Legal Entity India)
Submits Form MD-14 - CDSCO (SUGAM)
To comply with Rule 34(2), a foreign manufacturer must appoint an Authorised Indian Agent (AIA).
AIA Mandatory Requirements
Legal Entity: Must be a registered business entity in India.
Wholesale Drug Licence: Must hold a valid Wholesale Licence in Form 20B and Form 21B issued by the State Licensing Authority (SLA).
Power of Attorney (PoA): Must execute a formal PoA authenticated by an Indian Embassy/Consulate or apostilled in the country of origin.
Regulatory Joint Responsibility: The AIA shares legal and regulatory responsibility with the foreign manufacturer for product quality, post-market surveillance, adverse event reporting, and recall management in India.
Technical Dossier: Device Master File (DMF) vs. Plant Master File (PMF)
The technical submission under Form MD-14 requires two comprehensive dossiers prepared according to the Fourth Schedule of MDR, 2017.
Complete Document Checklist for Form MD-14
To avoid CDSCO query cycles or rejection, compile documentation strictly according to official checklists:
1. Legal & Administrative Documents
Executed Power of Attorney (PoA) duly apostilled or legalised by the Indian Embassy.
Valid Wholesale Licence (Form 20B/21B) of the Authorised Indian Agent.
Free Sale Certificate (FSC) issued by the National Competent Authority of an GHTF/IMDRF member country (USA, EU, Japan, Canada, Australia).
Constitution details of the foreign manufacturer and the AIA.
2. Site & Quality Documents
Valid ISO 13485:2016 Certificate for the manufacturing site.
Plant Master File (PMF) complying with Fourth Schedule requirements.
Full list of manufacturing equipment and quality control instruments.
3. Device Technical Documents
Device Master File (DMF) detailing device description, intended use, materials, and specifications.
Biocompatibility, bench testing, and software validation studies (if applicable).
Risk Management Report adhering to ISO 14971 standards.
Shelf-life study reports and accelerated/real-time stability data.
Clinical evaluation data or published clinical evidence.
4. Commercial & Regulatory Information
Artwork for Indian outer/inner packaging labels adhering to Rule 84 (MDR, 2017).
Instructions for Use (IFU) / Package Insert.
Official regulatory fee payment receipt generated via Bharatkosh (bharatkosh.gov.in).
Step-by-Step MD-14 to MD-15 Workflow
Step 1: Classification & Strategy
Step 2: Appoint AIA & Execute PoA
Step 3: Compile DMF & PMF Dossiers
Step 4: Pay Government Fees via Bharatkosh
Step 5: Submit Form MD-14 on SUGAM Portal
Step 6: CDSCO Technical & Document Review] ── (If Queries Raised) ──► [Submit Query Response
Step 7: Subject Expert Committee (SEC) Review] (Mainly for Class C/D or Novel Devices)
Step 8: Grant of Import Licence on Form MD-15
CDSCO Official Fee Structure
Fees are payable through the integrated Bharatkosh portal in US Dollars (USD) or Indian Rupees (INR) equivalent as specified in the Third Schedule of MDR, 2017.
Note: Additional commercial costs include embassy legalisation/apostille fees, local laboratory test testing fees (if directed by CDSCO), and regulatory consulting expenses.
Real-World Timelines & Process Bottlenecks
While statutory timelines exist, actual processing time depends heavily on dossier completeness, device risk category, and technical query responses.
ESTIMATED TIMELINE BREAKDOWN
Activity - Indicative Duration
Dossier Compilation & PoA - 4 – 8 Weeks
CDSCO Initial Review - 6 – 12 Weeks
Technical Queries & SEC - 4 – 12 Weeks (if triggered)
Licence Issuance (MD-15) - 2 – 4 Weeks
Class A & B Devices: Typically process faster (approx. 3 to 5 months overall).
Class C & D Devices: May require Subject Expert Committee (SEC) clinical review or site inspections (approx. 6 to 9 months overall).
Licence Validity and Retention Requirements
Under Rule 38 of MDR, 2017, an import licence issued on Form MD-15 remains perpetually valid, provided the licensee pays the required licence retention fee prior to the completion of every 5-year period.
Retention Rules
Payment Window: Retention fees must be submitted before the expiration of 5 years from the date of licence issuance.
Consequence of Default: If the retention fee is not paid on or before the due date, a late fee is levied. Continued non-payment results in the cancellation or rendering invalid of the MD-15 licence.
Common Reasons for CDSCO Queries & Application Delays
Mismatched Manufacturer Names/Addresses: Inconsistencies between ISO 13485, FSC, and PoA.
Incomplete Power of Attorney: Missing mandatory authorization clauses or lack of proper apostille/legalisation.
Inadequate Biocompatibility Reports: Submitting summary certificates instead of full raw data and testing protocols.
Non-Compliant Artwork: Labels missing the AIA name/address, MD-15 licence number placeholder, or statutory Indian consumer details.
Invalid Free Sale Certificate: Submitting FSCs from non-GHTF countries without proper backup data.
Outdated ISO 13485 Certificates: Expiry of QMS certificates during the evaluation period.
Unclear Device grouping: Attempting to group distinct, non-similar devices under a single MD-14 application.
Inadequate Software Validation: Missing stand-alone software or SaMD validation documentation.
Insufficient Shelf-Life Studies: Submitting real-time data that does not cover the full claimed expiry period without accelerated backup data.
Delayed Query Response: Failure to answer CDSCO review queries within the specified statutory period.
2026 Regulatory Considerations
National Single Window System (NSWS) Integration: CDSCO continues expanding unified filings across NSWS and SUGAM to streamline clearance processes.
Enhanced Post-Market Vigilance: Importers must maintain structured Materiovigilance Programme of India (MvPI) compliance pathways to report adverse events within mandated timeframes.
Mandatory Unique Device Identification (UDI): Increased harmonization with global UDI tracking protocols for high-risk devices clearing Indian customs.
Regulatory Compliance Checklist for Importers
Device Classification: Verify risk class under official CDSCO classification notifications.
Agent Appointment: Confirm Authorised Indian Agent holds valid Wholesale Licences (20B/21B).
Legal Verification: Ensure Power of Attorney is apostilled or legalised.
Dossier Preparation: Complete Device Master File and Plant Master File per Fourth Schedule format.
Quality System: Verify overseas facility holds valid ISO 13485:2016 certification.
Fee Payment: Calculate and pay official site and device fees via Bharatkosh.
Submission: Submit Form MD-14 on the SUGAM portal and track query notifications.
Post-Approval: Maintain MvPI reporting systems and schedule retention fee payments every 5 years.
Frequently Asked Questions
1. Can a foreign manufacturer hold an MD-15 import licence directly?
No. Foreign manufacturers cannot apply directly for an import licence. They must appoint an Authorised Indian Agent (AIA) holding a valid wholesale drug licence in India.
2. What is the validity period of a Form MD-15 import licence?
Form MD-15 has perpetual validity, provided that the required retention fee is paid every 5 years as specified under the Medical Devices Rules, 2017.
3. Does a Class A device require an MD-15 import licence?
Yes. All notified medical devices across Class A, B, C, and D require regulatory filing on Form MD-14 and the issuance of Form MD-15 prior to commercial import into India.
4. Can an Authorised Indian Agent be changed after licence grant?
Yes. Changing or adding an AIA requires a new application, updated Power of Attorney, and formal submission to CDSCO.
5. What happens if CDSCO issues a deficiency query on Form MD-14?
The applicant must submit a detailed response addressing all technical or administrative deficiencies on the SUGAM portal within the specified timeframe.
Conclusion
Navigating the CDSCO import licensing landscape requires a structured approach: establishing a verified risk classification, appointing a qualified Authorised Indian Agent, compiling robust DMF/PMF technical dossiers, and completing the Form MD-14 filing on the SUGAM portal. Compliance continues post-issuance through mandatory 5-year retention payments, label compliance, and post-market materiovigilance reporting.
Comments
Post a Comment